Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rivaroxaban in acute venous thromboembolism patients taking strong CYP3A4 inducers
NL-OMON32634Phase 2Not yet recruiting
- Sponsor
- Bayer
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rivaroxaban in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE), sponsored by Bayer. Primary endpoint: Population pharmacokinetics/pharmacodynamics of adapted rivaroxaban dosing. Planned start Dec 2008; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON32634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32634.